Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

by Medical Finance
in Coronavirus
Study: Evaluation of Antiviral Effect against SARS-CoV-2 Propagation by Crude Polysaccharides from Seaweed and Abalone Viscera In Vitro. Image Credit: mnimage / Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

During the early stages of the COVID-19 pandemic, where there was an absence of treatment or vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), several studies conducted worldwide screened for substances that could inhibit SARS-CoV-2 infection, replication, and propagation from marine bioactive compounds that included polyphenols, polysaccharides, and carotenoids.

Polyphenols obtained from brown algae, also known as phlorotannins, were predicted to be an inhibitor of SARS-CoV-2 in silico. Siphonaxanthin, which is a marine carotenoid obtained from Codium fragile, could inhibit the entry of SARS-CoV-2 pseudovirus into the cell in vitro.

Recent studies have indicated that iota‐carrageenan can inhibit SARS-CoV-2 replication in several cell lines. It has also been reported to inhibit the replication of SARS-CoV-2 variants, alpha, beta, gamma, and delta. Additionally, an iota‐carrageenan nasal spray was also identified that reduced the risk of SARS-CoV-2 infection in healthcare workers who managed patients with COVID-19 by 79.8 percent.

Furthermore, several marine sulfated polysaccharides were observed to inhibit SARS-CoV-2 entry by interfering with the interaction between the ACE2 receptor of the host cell and the SARS-CoV-2 spike protein in vitro. A previous study showed that crude polysaccharides (CPs) from seaweed and abalone viscera could effectively inhibit SARS-CoV-2 pseudovirus entry.

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

Study: Evaluation of Antiviral Effect against SARS-CoV-2 Propagation by Crude Polysaccharides from Seaweed and Abalone Viscera In Vitro. Image Credit: mnimage / ShutterstockStudy: Evaluation of Antiviral Effect against SARS-CoV-2 Propagation by Crude Polysaccharides from Seaweed and Abalone Viscera In Vitro. Image Credit: mnimage / Shutterstock

About the study

The study involved cytotoxicity evaluation of CPHF, CPSH, and CPAV followed by plaque reduction assay using different concentrations of CPHF, CPSH, and CPAV. The 50 percent tissue culture infectious dose (TCID50) was determined based on whether a cytopathic effect occurred or not. 

An immunofluorescence assay was performed to assess the propagation of SARS-CoV-2. Western blotting was carried out to examine the expression of the viral spike (S) and nucleocapsid (N) proteins followed by RNA isolation and quantitative RT‐PCR (qRT‐PCR) using RNA‐dependent RNA polymerase (RdRp) and nucleocapsid (N) primers. Finally, a reporter assay was performed using SARS‐CoV‐2 pseudovirus.

Evaluation of Antiviral Effect against SARS-CoV-2 Propagation by Crude Polysaccharides from Seaweed and Abalone Viscera In Vitro

Study findings

The results indicated that the crude polysaccharide from abalone viscera was a little more toxic as compared to the other two CPs. Plaque formation was observed to be reduced in a dose-dependent manner by CPs, with 500μg/mL of CPs reducing plaque formation by 98 percent. Plaque formation was reported to be reduced by over 60 percent by CPHF and CPSH and 40 percent by CPAV for cells treated with 0.8 μg/mL CP concentrations before SARS‐CoV‐2 infection. Additionally, the concentrations with 50 percent inhibitory concentration (IC50) of CPHF, CPSH, and CPAV were observed to be 0.35, 0.56, and 4.37 μg/mL, respectively.

The crude polysaccharides were found to inhibit SARS-CoV-2 infection at 3 days and 4 days post-infection. The infectivity of SARS-CoV-2 in the presence of 500 μg/mL of CPAV, CPSH, and CPHF before the cells were treated with the virus was 16.5 ± 2.5 percent, 9.5 ± 3.2 percent, and 8.7 ± 2.7 percent. At the same time, it increased to 47.8 ± 6.6 percent, 48.7 ± 3.3 percent, and 45.7 ± 1.4 percent when cells were treated with CPs following virus infection.

The results also indicated that cells treated with CPs before virus infection did not express the viral S and N proteins. However, their expression was observed in cells treated with CPs after virus infection. Moreover, RdRp and N RNA copies were not detected in cells pre-treated with CPs while RdRp and N RNA copies were slightly increased in cells treated with CPs after infection. Also, SARS‐CoV‐2 pseudovirus cell entry was found to be strongly inhibited when pre-treated with CPs. However, the inhibitory effect was low when post‐treating with CPs.

Therefore, the current study demonstrated that SARS‐CoV‐2 propagation before and after viral infection could be inhibited by the crude polysaccharides of seaweed and abalone viscera. These crude polysaccharides need to be further purified and characterized to be used to develop therapeutics and prophylactics against the spread of the virus. Additional studies are required to examine the pharmacokinetics, perform nonclinical trials, and clarify the antiviral mechanisms when the structures of the marine polysaccharides are analyzed.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

UGA researchers develop nanotechnology-based optical sensors for rapid coronavirus detection

UGA researchers develop nanotechnology-based optical sensors for rapid coronavirus detection

by Medical Finance
July 3, 2022
0

A University of Georgia nanotechnology research group entered the race to develop a rapid test for COVID-19 in August 2020,...

Study: Evidence of SARS-CoV-2 Reinfection: Analysis of 35,000 Subjects and Overview of Systematic Reviews. Image Credit: Corona Borealis Studio/Shutterstock

Researchers assess prevalence of SARS-CoV-2 reinfections

by Medical Finance
July 3, 2022
0

In a recent study posted on Preprints with The Lancet*, researchers assessed the prevalence of severe acute respiratory syndrome coronavirus 2...

Study: Glasses and risk of COVID-19 transmission - analysis of the Virus Watch Community Cohort study. Image Credit: DimaBerlin/Shutterstock

Study finds a significant reduction in the risk of COVID-19 infection among those who always wear glasses

by Medical Finance
July 3, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers analyzed the influence of the use of spectacles on coronavirus...

Study: Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice. Image Credit: Fit Ztudio/Shutterstock

Insights into the pathogenesis of the previous and circulating SARS-CoV-2 variants in mice

by Medical Finance
July 3, 2022
0

A recent article posted to the bioRxiv* preprint server presented the diverse pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Image Credit: MIA Studio/Shutterstock

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

by Medical Finance
July 3, 2022
0

Small molecules with antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can offer therapeutic possibilities for the...

Study: Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Image Credit: joshimerbin/Shutterstock

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

by Medical Finance
July 3, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers tested the efficacy of sotrovimab, a neutralizing monoclonal antibody...

Next Post
Estimated number of new cases in 2020. worldwide, both sexes, all ages (left), and estimated number of deaths in 2020. worldwide, both sexes, all ages (right). (Data source: GLOBCAN 2020, Graph production: Global Cancer Observatory (http://gco.iarc.fr/))

Anti-cancer drug targets: Tools for research

Study: The immune response to COVID-19: Does sex matter? Image Credit: Sagittarius_13/Shutterstock

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Using Best-Worst Scaling to investigate younger adult Canadians’ preferences for COVID-19 vaccination and public health measures: an observational study. Image Credit: Shark9208888/Shutterstock
    Assessing COVID-19 vaccination preferences of younger adults in Canada
  • Study: Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Image Credit: Huen Structure Bio
    Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply